The MCI-Park mice are compound mutant (Ndufs2fl/fl; DAT IREScre/+) animals in which Ndufs2, a gene encoding a core subunit of the mitochondrial respiratory chain, is selectively inactivated in ...

This interactive resource organizes decades of data on biomarkers for Alzheimer's disease. Biomarker measurements from the cerebrospinal fluid and blood are curated from the primary literature and ...

Do you know a conference you think we should list? Let us know by sending us an email with the details to [email protected].

When Alois Alzheimer described the case of Auguste D. to an audience of fellow psychiatrists in Tuebingen, Germany, in 1906, what set her case apart was the fact that her dementia appeared before she ...

Eisai and Biogen yesterday announced positive topline results from the Phase 3 Clarity trial of their anti-amyloid antibody lecanemab. The drug slowed decline on the primary endpoint, CDR-SB, by 27 ...

The slight slowing of cognitive decline achieved by Leqembi and perhaps by Aduhelm has revived debate around how much change is needed to be “clinically meaningful.” Two recent papers—one a report ...

In a watershed moment for the field, the U.S. Food and Drug Administration today approved the first Alzheimer’s treatment that tackles the underlying disease pathology. Biogen and Eisai’s anti-amyloid ...

If enhancing memory with light and sound seems futuristic, then welcome to the future. Or so some scientists say. Results from four early stage clinical trials on mild Alzheimer’s disease were ...

Alzheimer’s researchers have long wished for better mouse models. That is now coming true. Scientists at the Jackson Laboratory in Bar Harbor, Maine, are cranking out numerous lines that express ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

Biogen’s hopes for a quick regulatory approval of its anti-Aβ antibody aducanumab may be dimming. An advisory panel convened by the U.S. Food and Drug Administration was unimpressed by the evidence ...

Will Biogen’s aducanumab become the first drug approved to slow progression of Alzheimer’s disease? Biogen’s licensing application for the biologic ran into headwinds at a U.S. Food and Drug ...